Small Cap Wrap – Eddie Stobart Logistics, Amryt Pharma, World High Life and more…


23 Dec 2020


*A corporate client of Hybridan LLP


Dish of the day

*Delighted to welcome One Heritage Group #IPO (OHG.L) to the Main Market today.
– Property development and management company focusing on the North West
– £18m total gross development value
– Looking to serve the rising demand in the residential market
– Successfully raised £930k @ 10p (market cap £3m).
– Use of proceeds to scale the business and facilitate completion of existing projects


Off the menu

No Leavers Today

What’s cooking in the IPO kitchen?

HSS Hire Group,HSS.L transfer from Main to Aim. Mkt Cap c. £70m. Recently raised £52.6m. Leading supplier of tool and equipment for hire in the United Kingdom and Ireland and has provided equipment hire services in the United Kingdom for more than 60 years, primarily focusing on the B2B market.  Due 14 Jan 2021.


Vector Capital to float on AIM, a commercial lending Group that offers secured loans primarily to businesses located in the UK. Substantially all of the Group’s loans are secured by a first legal charge against real estate. The Group’s customers typically borrow for general working capital purposes, bridging, land development and acquisition. As of 30 September 2020, the Group had a loan book of £34.7m, with an average loan size of approximately £0.57m. Raising £3.1m at 38p. Mkt Cap £16m.

Due 29th December. 


VH Global Sustainable Energy Opportunities plc, a closed-ended investment Company focused on making sustainable energy infrastructure investments, today announces intends to launch an initial public offering  of shares on the Official List (Premium) of the Main Market of the London Stock Exchange.  Due by Early Feb 2021.


Eddie Stobart Logistics (LON:ESL) converting to an AIM investing company. Name change to Logistics Development Group. Focus sectors: logistics, transport, warehousing and e-fulfilment assets. £9m to be raised via a placing and subscription and up to £7m via open offer. Market cap c.£35.1m. Due New Years Eve.


Reverse take-over under rule 14 by MelodyVR (AIM:MVR) Group of Rhapsody International, trading as Napster.  Upon completion of the transaction, Napster will be a wholly-owned subsidiary of MelodyVR Group. The enlarged group will combine the service offerings of MelodyVR and Napster, offering music fans a consolidation of music artist’s repertoires including recorded music, short form video content, long form video content, digitally ticketed live streams, educational videos and immersive AR/VR content, into one premium subscription product. Raising $10.1m. Market cap £92.4m at 3.75p.

Due 29 December.

Banquet Buffet

Amryt Pharma 195p  £349m (LON:AMYT)

The global, commercial-stage biopharmaceutical Company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases announced that the U.S. Food and Drug Administration has granted orphan drug designation for AP103 for the treatment of Dystrophic Epidermolysis Bullosa (DEB).  AP103 is based on Amryt’s gene-therapy platform technology and offers a potential treatment for patients with DEB, a subset of EB.  


SEC Newgate 46p  £11.16m (LON:SECG)

The insight-driven global strategic communications group that works at the nexus of business, politics, communities, markets and media, has signed agreements to acquire a 60% shareholding in four tranches (15% per annum until 2024) in Orca Affairs GmbH in line with the Group’s Strategic Plan 2021/2023 and stated acquisition strategy. Orca Affairs, based in Berlin, has a strong track record in public and corporate affairs at a national level. The agency’s specialist consultants offer a broad portfolio of services, including institutional events, communications strategies, public affairs, media relations and digital consultancy, brand management, media training and coaching to companies and public institutions across a diverse range of sectors. The initial consideration comprises a completion cash payment of EUR0.7m for a 15%  stake.  The total Acquisition consideration is subject to a minimum of EUR2.2m and is capped at EUR3.5m. In the year ended 31 December 2019, Orca Affairs’ turnover was EUR10.5m with profit before tax of EUR2.2m in part influenced by short-term extraordinary business which is not continuing into 2021.  The Acquisition will be earnings enhancing in 2021.


World High Life 1.9p  £4.4m (AQSE:LIFE)

Wholly owned subsidiary, London-based Love Hemp Limited (Love Hemp), has successfully launched a 10 SKU Love Hemp product line across 880 Holland & Barrett stores throughout the UK and Ireland, and online at Tony Calamita, CEO at Love Hemp says: “This is a significant relationship not only in its scale, but also because Love Hemp and Holland & Barrett have implemented a ground-breaking education and awareness program designed to inform consumers around the benefits of CBD. The opportunity to play such a leadership role in the category is directly aligned with our values. It is important to invest with partners such as H&B to increase knowledge and confidence for consumers, so they know they are buying credible products from credible retailers.”


Polarean Imaging  68.5p  £111m (LON:POLX)

The medical imaging technology Company, with a proprietary drug device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, provides an update regarding the status of its New Drug Application (NDA) with the US Food and Drug Administration (FDA). Polarean has received notification of acceptance of the Company’s NDA by the FDA.  The FDA has confirmed that the review will follow the standard review time frame with a target Prescription Drug User Fee Act action date of 5 October 2021. The Company plans to make full use of this time with regards to commercialisation and launch preparation.


Bluejay Mining 13.9p  £135m (LON:JAY)

The exploration and development Company with projects in Greenland and Finlandhas signed a Master Distribution Agreement  with a large, long established Asian Conglomerate with global interests in Metals and Mining for the sale of up to 340,000 tonnes per annum of ilmenite from the Company’s flagship Dundas Project, Greenland .


MaxCyte 485p  £327m (LON:MXCT)

The a global cell-based therapies and life sciences Company, today announced an update on trading for the full year 2020 and progress of the CARMA programme. Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects  financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021.  MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group’s CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January.


Immotion Group 3.65p  £15m (LON:IMMO)

Immotion Group, the UK-based immersive entertainment group updated the market on current trading. Despite current Covid-19 challenges, the Company has seen un-audited revenue increase steadily in recent weeks. The Group launched Let’s Explore Oceans (LEO) in mid-October and total group revenue for October was £369k and November was £573k, an increase of 21%, and 87% respectively compared to September (prior to the launch of LEO). Since the launch in mid-October 2020, sales of the Home Based Entertainment product, LEO have exceeded expectations with total units sold up to and including 22 December, of over 11,000 generating total retail sales, including VAT, exceeding £800,000.  “The Location Based Entertainment (LBE) business continues to be impacted by the Covid-19 pandemic, and whilst our UK operations are now closed again as a result of recent UK Government requirements, we have seen one further USA site re-open since our last update (and none closed). Whilst capacities remain restricted in many, we are, in the circumstances, encouraged by demand. The Nevada state authorities have recently limited user numbers to 25% of normal capacity in certain attractions, which will be reviewed in mid-January 2021. This will inevitably impact our revenues in this location significantly in this period.”  “Whilst the short-term impact of Covid-19 is very frustrating, we remain confident that demand will be very strong for our LBE offering when any sort of normality returns.  This would result in very substantial uplifts in revenue and contribution from our LBE business.”


Beeks Financial Cloud  97p  £50.15m (LON:BKS)

The cloud computing and connectivity provider for financial markets announced the appointment of Kevin Covington to the Board as an independent Non-Executive Director effective from 4 January 2021. Kevin has had more than 30 years’ experience working internationally in the financial services industry for both vendors and banks, with a particular focus on M&A and advisory. Kevin currently runs a boutique advisory firm, Change Alley, which helps develop and grow organisations in the fintech sector. Kevin also acts as an adviser and mentor to a number of companies in the sector, including Adaptive Financial Consulting, KA2, Enyx and, prior to its acquisition by Beeks, Velocimetrics. Previous positions include CEO of a VC backed Australian technology company, Metamako, which was acquired by Silicon Valley based Arista Networks in late 2018 and CEO at technology company ITRS Group Limited.


Gooch & Housego  1185p  £297m (LON:GHH)

The specialist manufacturer of optical components and systems, announces that G&H photonic systems and components have been successfully launched in space and are performing an important role in Japan’s new inter-satellite network. G&H photonics technology is at  the heart of a laser communication system known as LUCAS (Laser Utilising Communication System), which uses hardware developed by Japan’s NEC Corporation for the Japan Aerospace Exploration Agency (JAXA), a government organisation. JAXA and NEC recently announced the launch of LUCAS on board the Optical Data Relay Satellite, which was launched from JAXA’s Tanegashima Space Center in Kagoshima, Japan, using an H-IIA rocket. The pioneering LUCAS system pushes the performance envelope in terms of data rates and latency with the aim of offering near real-time availability of satellite data. Use of the system will show how laser communications can be a viable solution for future high-speed and scalable space communications.


InfraStrata 46.5p  £30.2m (LON:INFA)

The UK quoted Company focused on strategic infrastructure projects and physical asset lifecycle management has conditionally raised, in aggregate, up to £7.4  m (before expenses) by way of a placing of new Ordinary Shares at a price of 45 pence per share to existing and new investors, as well as an Open Offer to be issued to Qualifying Shareholders at a price of 45 pence per share.  The net proceeds from the Placing will strengthen the Company’s balance sheet and continue to enable it to tender for and win larger contracts , as well as to provide capital expenditure for inter alia, the acquisition of a robotic welding panel line and other yard refurbishment programmes in preparation for the potential award and subsequent execution of fabrication contracts; and provide sufficient working capital to improve negotiating position on new contract opportunities by removing the potential for an emphasis of matter statement within upcoming full year results.


Head Chef

Derren Nathan

0203 764 2344

[email protected]

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II              Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.


Please enter your comment!
Please enter your name here